Reckitt Benckiser Group PLC
Search documents
Reckitt Benckiser Group PLC (OTC:RBGLY) Maintains Hold Rating Amid Strategic Turnaround
Financial Modeling Prep· 2025-10-27 23:03
Core Insights - Reckitt Benckiser Group PLC is undergoing a strategic turnaround focused on growth and improved execution in the consumer goods sector, competing with Procter & Gamble and Unilever [1] Financial Performance - Deutsche Bank maintains a "Hold" rating for Reckitt Benckiser with a stock price of $15.74 and raised its price target to 5,700 GBp, indicating a cautiously optimistic outlook [2][6] - RBC Capital Markets increased its price target from £60 to £64, maintaining an outperform rating, supported by Reckitt's consistent mid-single-digit growth and the "Fuel for Growth" plan [3][6] - Reckitt's shares are currently valued at approximately 18 times earnings for 2026, compared to around 20 times for the broader European consumer sector, despite a 17% increase in share price this year [4][6] Growth Prospects - Emerging markets for Reckitt are expected to achieve double-digit organic growth in 2025, contributing positively to the company's outlook [4] - The divestment of the Essential Home and Mead Johnson Nutrition units is anticipated to enhance management's focus on core operations [5]
RECKITT BENCKISER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Reckitt Benckiser Group PLC - RBGLY
GlobeNewswire News Room· 2025-07-16 02:10
Core Viewpoint - A securities class action lawsuit has been filed against Reckitt Benckiser Group PLC for failing to disclose material information during the Class Period, which may have led to economic losses for investors [3][4]. Group 1: Lawsuit Details - Investors who purchased Reckitt's American Depositary Shares (ADSs) between January 13, 2021, and July 28, 2024, have until August 4, 2025, to file lead plaintiff applications [1][2]. - The lawsuit alleges that Reckitt and certain executives violated federal securities laws by not disclosing risks associated with their cow's milk-based formula, Enfamil, which could lead to increased legal claims and impact sales [3][4]. Group 2: Legal Representation - Kahn Swick & Foti, LLC, a prominent securities litigation law firm, is representing the plaintiffs in this case [5]. - The firm has a strong track record, being ranked among the top 10 firms nationally based on total settlement value [5].